TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18-65 years of age~* Chronic hepatitis C genotype 1~* HCV treatment naïve, or without sustained virologic response on prior PEG-INF/RBV treatment~* Body mass index (BMI) 18 - 35 kg/m2, inclusive; minimum weight 45 kg~Exclusion Criteria:~* Liver cirrhosis~* Decompensated liver disease or impaired liver function~* Medical condition associated with chronic liver disease other than chronic hepatitis C~* Positive for hepatitis B or HIV infection at screening~* History of alcohol consumption exceeding 2 standard drinks per day when averaged over the course of a given week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: EXPERIMENTAL): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a primary diagnosis of MDE, diagnosed according to DSM-5® confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has had the current MDE for \<12 months~* The patient has current comorbid Generalized Anxiety Disorder (GAD) according to DSM-5®. The diagnosis was made prior to the current MDE~* The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥ 22 at the Baseline Visit~* The patient has a Hamilton Anxiety Rating Scale (HAM-A) score ≥ 20 at the Baseline Visit~Exclusion Criteria:~* The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria), established as the primary diagnosis, other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview.~* The patient has a history of previous major depressive episodes considered as treatment resistant, defined as inadequate response (incomplete or no therapeutic response) to two prior courses of at least 6 weeks of conventional antidepressant drugs in adequate dosages or, the patient has treatment-resistant depression in the investigator's opinion.~Other in- or exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): 10-20 mg vortioxetine tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages eligible for study: 18 years and above, Genders eligible for study: both~* Patients who have a life expectancy of at least 12 weeks~* Patients with histologically or cytologically documented Hepatocellular Carcinoma (HCC)~* Patients must have at least one tumor lesion that meets both of the following criteria: (1) Accurately measured in at least one dimension according to RECIST (Response Evaluation Criteria in Solid Tumors) (2) Not previously treated with local therapy~* Patients who have an ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) of 0, 1, or 2~Exclusion Criteria:~* Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta \[Noninvasive papillary carcinoma\], Tis \[Carcinoma in situ: flat tumor\] \& T1 \[Tumor invades subepithelial connective tissue\]). Any cancer curatively treated \> 3 years prior to entry is permitted~* Renal failure requiring hemo- or peritoneal dialysis~* History of cardiac disease~* Active clinically serious infections~* Known history of human immunodeficiency virus (HIV) infection~* Known central nervous system tumors including metastatic brain disease~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Nexavar, BAY43-9006) (Type: EXPERIMENTAL): Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
- Placebo (Type: PLACEBO_COMPARATOR): Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Participants who submit written informed consent for study entry.~2. Participants aged greater than or equal to 20 and less than 85 years of age at the time of obtaining informed consent.~3. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version or diagnosed with insomnia associated with psychiatric or physical disorder(s).~4. Participants with both of the following conditions which are persistent for 4 weeks or longer before the start of observation period:~   * Total sleep time is less than or equal to 390 minutes for more than or equal to 3 days a week~  * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week~5. Participants with data at least 2 consecutive days in diary entries during observation period and confirmed to meet the following two criteria:~   * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week~  * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week~Exclusion criteria:~1. Participants with a present or history of the following disease specified in~   Mini-International Neuropsychiatric Interview (M.I.N.I.) Japanese version 5.0:~  * Risk of suicide~  * (Mild) manic episode~  * Post-traumatic stress disorder (PTSD)~  * Alcohol dependence and abuse~  * Drug (non-alcohol) dependence and abuse~  * Anorexia nervosa~  * Bulimia nervosa~  * Anti-social personality disorder~2. Participants with pharmacologically induced insomnia (drug-induced insomnia).~3. Participants with comorbid primary sleep disorders (circadian rhythm disorder, restless legs movement syndrome, periodic limb movement disorder, sleep apnea syndrome, etc.) other than primary insomnia.~4. Participants with symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturation, and cough.~5. Participants with unstable primary disease presenting insomnia during 4 weeks before the start of observation period.~6. Participants with organic mental disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone 1 mg- Elderly (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg- Elderly (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg- Non-elderly (Type: EXPERIMENTAL): None
- Eszopiclone 3 mg- Non-elderly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of understanding and complying with all aspects of the protocol.~* Signed Informed Consent.~* Capable of understanding the plasmapheresis information sheet and sign it.~* Healthy male or female volunteers, age 18 years or older.~* Women must have negative pregnancy test (human chorionic gonadotropin \[HCG\] based assay).~* Women must have sufficient methods of contraception (eg, intrauterine device, oral contraception, etc).~* No clinically relevant abnormalities in medical history and general physical examination.~* Standard health insurance.~Exclusion Criteria:~* Pregnancy or lactation.~* Tattoos within the last 3 months.~* Subject was treated therapeutically with fresh frozen plasma, blood, or plasma-derived products within the last 6 months.~* Hypersensitivity to blood products or plasma proteins.~* History of angioedema.~* History of coagulation or bleeding disorder or any other known abnormality affecting coagulation, fibrinolysis, or platelet function.~* Any clinically significant abnormal laboratory values.~* IgA deficiency.~* Seropositivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus type 1 or type 2 antibodies.~* Symptoms of a clinically relevant illness within 3 weeks before the first trial day.~* History of or suspected drug or alcohol abuse.~* Subjects currently participating in another clinical study.~* Any investigational medicinal product administration within the last 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Octaplas LG (Type: EXPERIMENTAL): Participants received 1200 mL of Octaplas LG intravenously once.
- Octaplas SD (Type: ACTIVE_COMPARATOR): Participants received 1200 mL of Octaplas SD intravenously once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Siyakhana Peer: Evaluating a Peer Recovery Coach Model to Reduce Substance Use Stigma in South African HIV Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
1. HEALTHCARE WORKER:~   1. Inclusion Criteria:~      * At least 18 years old~     * Employed as a healthcare worker (e.g., community health worker, nurse, supervisor, etc.,) for one of the partner healthcare worker teams that provides HIV re-engagement services~  2. Exclusion Criteria:~      * Unable or unwilling to complete informed consent and study procedures in English, isiXhosa, or Afrikaans~2. PATIENT:~   1. Inclusion Criteria:~      * At least 18 years old~     * Living with HIV~     * Problematic alcohol or other drug use defined by either: a) AUDIT-C score ≥ 2; or b) self-report illicit drug use within past 3 months~     * Seen by a healthcare worker from one of the healthcare teams partnered with this study because of recent disengagement in HIV care~  2. Exclusion Criteria:~      * Unable or unwilling to complete informed consent and study procedures in English, isiXhosa, or Afrikaans

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enhanced Treatment as Usual (Healthcare Workers) (Type: NO_INTERVENTION): Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
- Siyakhana - P (Healthcare Workers) (Type: EXPERIMENTAL): Providers working with PRC. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.
- Enhanced Treatment as Usual (Patients) (Type: NO_INTERVENTION): Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
- Siyakhana - P (Patients) (Type: EXPERIMENTAL): Patients seen by the team of health care workers with an integrated PRC. Patients will have the opportunity to meet with the PRC for about 3-months after their baseline assessment. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Injury Vocational Integration Program (SCI-VIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 65 years old - Spinal cord injured as a result of trauma or disease~* Medically and neurologically stable~* Lives within the metropolitan area that is proximal to the VAMC (Cleveland, Dallas, Houston, San Diego, St. Louis)~* Has access to transportation~* Expresses an interest in competitive employment as an outcome of participation~* Willingly signs a consent form indicating voluntary and informed participation in the study~Exclusion Criteria:~* Medically and/or surgically unstable~* Unwilling to complete the consenting process~* Mentally impaired such that independent reasoning and judgment jeopardize safety of self and others~* Currently involved in untreated alcohol and/or drug dependency~* Employed in a compensated job at the time of recruitment and earning above SGA ($940/month in 2008) - Lives more than approximately 100 miles from the participating VAMC SCI Center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): SCI-VIP: Supported employment implemented for veterans with spinal cord injury
- Arm 2 (Type: PLACEBO_COMPARATOR): Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Re-boosting of HIV-1 Infected Subjects With Vacc-4x

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed immunization regimen with Vacc-4x active and stopped ART (at Week 28) in the CT-BI Vacc-4x 2007/1 study. (No re-start of ART is required).~2. Documented pre-study CD4 cell count ≥400x106/L.~3. Documented pre-study viral load \< 300 000copies/mL.~4. Signed informed consent.~Exclusion Criteria:~1. Reported AIDS-defining illness within the previous year.~2. Malignant disease.~3. On chronic treatment with immune-suppressive therapy.~4. Unacceptable values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine values \>1.5 x upper limit of normal (ULN), and AST, ALT and alkaline phosphatase (ALP) values \>2.5 x ULN.~5. Concurrent chronic active infection such as viral hepatitis B or C or tuberculosis.~6. Pregnant or breastfeeding women.~7. Women of childbearing potential not using reliable and adequate contraceptive methods (defined as: use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; practicing abstinence; sterile) during the 5 weeks re-boosting period including the DTH and for 2 weeks after the DTH test, or sexually active male subjects with partners of child bearing potential unwilling to practice effective contraception during the 5 weeks re-boosting period including the DTH and for 12 weeks after the DTH-test.~8. Current participation in other clinical therapeutic studies.~9. Incapability of compliance to treatment protocol, in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: f

Study Arms:
- Re-boosting with Vacc-4x (Type: EXPERIMENTAL): Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in A5257 and intent to enroll in A5001 (ALLRT)~* Signed informed consent~* For A5257 inclusion criteria, please see ClinicalTrials.gov identifier NCT00811954~Exclusion Criteria:~* Diabetes mellitus, (fasting plasma glucose ≥ 126 mg/dL on two occasions or on hypoglycemic medications).~* Known cardiovascular disease (history of myocardial infarction \[MI\], coronary artery bypass graft surgery, percutaneous coronary intervention, stroke, transient ischemic attack, or peripheral arterial disease with ankle-brachial index of less than 0.9 or claudication)~* Uncontrolled hypothyroidism or hyperthyroidism which in the opinion of the site investigator would affect substudy participation~* Current use of statins, fish oil (greater than 2 grams per day), fibric acid derivatives, or niacin (more than 1000 mg per day) (NOTE: Current use of fish oil and niacin is defined as receiving treatment in the 8 weeks prior to study entry)~* Intention to start pharmacological or surgical intervention for weight loss~* Use of any ART in the 30 days before study entry~* For A5257 exclusion criteria, please see ClinicalTrials.gov identifier NCT00811954

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
- Cohort B (Type: None): RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
- Cohort C (Type: None): DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has less than 24 weeks previous treatment with antipsychotics (cumulative; lifetime)~  * Subject treated with aripiprazole can receive an additional 1 year of treatment at ≤5 mg/day, and this treatment will not be considered as part of the 24 weeks of previous treatment with antipsychotics~* Has less than 4 years elapse since the initial onset of active-phase of symptoms~* Has a body mass index (BMI) of \<30 kg/m\^2~* Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after the last dose of study drug~* Subject meets the criteria for a primary diagnosis of schizophrenia, schizophreniform disorder, or bipolar I disorder~* For bipolar I disorder, must have been experiencing an episode of acute mania within ≤14 days prior to Visit 1~* Suitable for outpatient treatment~* Additional criteria may apply~Exclusion Criteria:~* Poses a current suicide risk~* Has a history of poor or inadequate response to treatment with olanzapine~* Has previously been treated with long-acting injectable antipsychotic medication within the 2 months prior to screening, or has \> 6 months cumulative life use, or has received treatment with electroconvulsive therapy in their lifetime~* Has initiated treatment with mood stabilizers (eg lithium, valproate, etc) \>2 months prior to Visit 1~* Has a positive drug screen for opioids, phencyclidine (PCP), amphetamine/methamphetamine, or cocaine~* Has taken opioid agonists (eg, codeine, oxycodone, tramadol, morphine) within the 14 days prior to Visit 1, or has taken opioid antagonists, including naltrexone and naloxone, within 60 days prior to Visit 1~* Taking any weight loss agents or hypoglycemic agents~* Has a clinically significant or unstable medical illness, condition, or disorder that would be anticipated to potentially compromise subject safety or adversely affect the evaluation of efficacy~* Has joined a weight management program or had significant changes in diet or exercise regimen within the past 6 weeks~* Has started a smoking cessation program within the past 6 months~* Has a history of diabetes~* Currently pregnant or breastfeeding or is planning to become pregnant during the study or within 30 days of the last study drug administration~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Coated bilayer tablet
- Olanzapine (Type: ACTIVE_COMPARATOR): Coated bilayer tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete